Oxford Biomedica plc (LON:OXB - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 663.18 and traded as low as GBX 559. Oxford Biomedica shares last traded at GBX 571.98, with a volume of 162,434 shares traded.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Jefferies Financial Group started coverage on Oxford Biomedica in a research note on Monday, March 23rd. They issued a "buy" rating and a GBX 827 price objective for the company. Deutsche Bank Aktiengesellschaft upped their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a "buy" rating in a report on Friday, January 9th. Finally, Stifel Nicolaus restated a "buy" rating and issued a GBX 950 price target on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Oxford Biomedica currently has an average rating of "Moderate Buy" and an average price target of GBX 687.

Read Our Latest Report on OXB

Oxford Biomedica Stock Up 3.1%

The firm's fifty day simple moving average is GBX 668.01 and its 200-day simple moving average is GBX 663.18. The company has a market cap of £713.31 million, a PE ratio of -21.92 and a beta of 1.10. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 116.74.

Oxford Biomedica (LON:OXB - Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, equities research analysts expect that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

See Also

• Five stocks we like better than Oxford Biomedica

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oxford Biomedica Right Now?

Before you consider Oxford Biomedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.

While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here